Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a highly potent nootropic peptide derived from angiotensin IV. Developed at Washington State University, Dihexa is approximately 7 orders of magnitude more potent than BDNF (brain-derived neurotrophic factor) in promoting neuronal connectivity. The peptide works primarily through the hepatocyte growth factor (HGF)/c-Met receptor system, which is crucial for synaptogenesis, dendritic spine formation, and long-term memory consolidation. Dihexa is orally bioavailable and can cross the blood-brain barrier, making it particularly interesting for cognitive research. Studies have shown it can improve cognitive function in animal models of Alzheimer's disease and other conditions characterized by cognitive decline.
| Research Status | Early research |
|---|---|
| Half-Life | Unknown |
| Administration | Oral or subcutaneous |
| Typical Dosage | 10-40 mg oral |
| Molecular Weight | 433.54 Da |
| Molecular Formula | C23H39N3O5 |
HGF/c-Met receptor system activation, promotes synaptogenesis and neuronal growth at picomolar concentrations.
All information is presented for Research Use Only (RUO). Not medical advice.